Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
US Stock Movement | Argenx (ARGX.US) surges over 10% pre-market as Vyvgart, its autoimmune myositis drug, meets primary endpoints in Phase III trial

US Stock Movement | Argenx (ARGX.US) surges over 10% pre-market as Vyvgart, its autoimmune myositis drug, meets primary endpoints in Phase III trial

智通财经智通财经2026/08/17 11:01
Show original

On Monday, Argenx announced that its autoimmune myositis drug Vyvgart achieved the primary endpoint in a Phase III study.

According to Jinse Finance APP, before the U.S. stock market opened on Monday, shares of European biotechnology company Argenx (ARGX.US) soared by 10.38%. The news comes as the company announced on Monday that its autoimmune myositis drug Vyvgart reached its primary endpoint in a Phase III study.

Argenx stated that, compared to placebo, patients treated with the drug showed a statistically significant improvement in their average total improvement score at week 52. Autoimmune myositis is a disease in which the immune system attacks the muscles and can quickly deprive patients of their ability to care for themselves.

Argenx is expanding the indications of its core drug Vyvgart, aiming to reach a broader patient population and strengthen its leadership in the field of autoimmune diseases. Analyst Michael Shah said these study results may serve as the basis for Vyvgart's approval in the United States.

Patients with this type of disease have long relied primarily on steroids and other broad-spectrum immunosuppressants. Rohit Aggarwal, a professor of medicine at the University of Pittsburgh and one of the leaders of the study, stated that this achievement is an important step towards helping patients reduce steroid use, because steroids have serious side effects.

However, the trial results were not entirely consistent, as Vyvgart did not demonstrate statistically significant efficacy in another group of patients with coexisting skin symptoms. Shah said it remains unclear how regulators will view this outcome.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!